Irish Brexit Event A Chance For Originator And Biosimilar Firms To Air Their Concerns
Executive Summary
A stakeholder event being organized by the Irish regulatory body, the HPRA, will hear views on the implications and risks of Brexit from associations representing the originator and generic/biosimilar industries, as well as the head of the HPRA’s task force on Brexit.
You may also be interested in...
Irish Regulator Prepares For Brexit-Related Problems, Offers To Take On More EU Work
Ireland’s healthcare products regulator HPRA says it is taking steps to deal with possible supply interruptions as a result of Brexit, and that it is ready to assume some of the regulatory workload that will result from the European Medicines Agency’s departure from the UK. A stakeholder workshop will be held at the end of August where pharma firms and distributors will be able to discuss Brexit-related concerns with the regulator.
19 Countries Have Submitted Bids To Host The EMA Post-Brexit
Formal offers to host the European Medicines Agency were received from 19 countries by the deadline of July 31. The European Commission will now begin assessing the bids on the basis of six criteria, with a final decision expected in November.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.